Itaconix continues to expand its commercial operation
Last updated: 22:18 01 Oct 2026 AEST, First published: 18:25 04 Dec 2020 AEDT
Snapshot
- Itaconix reiterates guidance as it unveils plans to more than double revenues
About the company
Itaconix PLC uses its proprietary plant-based polymer technology platform to produce and sell specialty ingredients that improve the safety, performance, and sustainability of consumer products.
The company's current ingredients are enabling and leading new generations of products in detergents, hygiene, and hair care. Itaconix's products contribute to the global low carbon economy.
How it is doing
Itaconix PLC (AIM:ITX, OTCQB:ITXXF, FRA:18G0), the AIM-listed maker of plant-based specialty polymers used in household detergents, has reiterated its recently upgraded revenue guidance, unveiling plans to more than double revenues to $30 million in the medium term.
The company also said it remained confident of delivering a small positive EBITDA (earnings before interest, tax, depreciation and amortisation) for the full year, alongside guidance of at least $14.8 million in revenue.
The medium-term target of $30 million will be achieved by expanding volumes with existing customers and landing new accounts from its current sales pipeline.
The group said momentum in its core Performance Ingredients division was expected to remain strong, supported by recurring revenues and growing demand in unit-dose detergent markets.
Itaconix PLC (AIM:ITX, OTCQB:ITXXF, FRA:18G0) shares soared in Friday morning's trade, rising 18% to 138.65p, after the company lifted its 2026 revenue outlook after first-half sales jumped 72% to a record $8.3 million, driven by growth across its main product segments.
The plant-based polymers specialist now expects full-year revenue of at least $14.8 million, compared with the $13.3 million analyst forecast cited in its statement.
Itaconix PLC (AIM:ITX, OTCQB:ITXXF, FRA:18G0) has secured the first customer supply agreement for its compact plastic-free dish detergent tablet, marking the product’s move towards commercial sales in North America.
The AIM-listed speciality polymers group will supply the 8-gram tablets to an unnamed purpose-driven North American brand through its SPARX Formulated Solutions business. Initial production will use pilot-scale tabletting capacity at Itaconix’s North American Innovation Center.